# EPHB2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- EPHB2 encodes a receptor tyrosine kinase critical for cell-cell communication, involved in development and exhibiting context-dependent tumor-suppressive or oncogenic roles in various cancers, including prostate, colorectal, and gastric malignancies.
- The gene's genomic locus at 1p36.12 is prone to loss of heterozygosity, and its promoter is regulated by transcription factors like Sp1, HIF1A, p53, and β-catenin, with methylation-sensitive CpG islands contributing to its silencing in cancer.
- EPHB2's structure includes an ephrin-binding domain (EBD), cysteine-rich region, fibronectin type III domains, a transmembrane helix, and a kinase domain, with post-translational modifications like glycosylation and phosphorylation modulating its activity and signaling through pathways such as RhoA/ROCK and Ras/MAPK.
- Pathogenic mutations in EPHB2, including missense mutations like R103C in the EBD and G632R in the kinase domain, are associated with specific cancers and congenital disorders, leading to either loss-of-function or gain-of-function phenotypes.
- EPHB2 serves as a host dependency factor for viruses like HCV and is exploited by pathogens such as H. pylori, while its expression on tumor cells can promote immune evasion by upregulating PD-L1.
- Several multi-kinase inhibitors like dasatinib and bosutinib target EPHB2, and investigational small-molecule inhibitors and antibody-drug conjugates are being developed, with EPHB2 expression levels serving as a predictive biomarker for response to certain therapies.

---

## Executive Summary & Key Metadata

The EPHB2 gene (Ephrin type-B receptor 2) encodes a receptor tyrosine kinase (RTK) belonging to the Eph receptor family, the largest subfamily of RTKs in the human genome. EPHB2 is a critical mediator of contact-dependent cell-cell communication, orchestrating developmental processes such as axon guidance, tissue boundary formation, and angiogenesis. In adult tissues, EPHB2 expression is frequently dysregulated in a broad spectrum of malignancies, where it exerts context-dependent tumor-suppressive or oncogenic functions. This manual provides a comprehensive, biophysically grounded reference covering the genomic architecture, three-dimensional protein structure, signal transduction mechanisms, pathogenic mutation landscape, pharmacogenomic relevance, and bioinformatic resources for EPHB2.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | EPHB2 |
| **UniProt Accession** | P29323 |
| **Representative PDB ID** | 1NUK (ligand-binding domain), 2HLE (kinase domain) |
| **Chromosomal Locus** | 1p36.12 |
| **Primary Molecular Function** | Receptor tyrosine kinase; ephrin-B ligand binding; bidirectional signal transduction |
| **Disease & Pathology Associations** | Prostate cancer, colorectal cancer, gastric cancer, melanoma, glioblastoma, congenital ptosis, and Kallmann syndrome |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The EPHB2 gene is located on the short arm of chromosome 1 at cytogenetic band 1p36.12 (GRCh38/hg38 coordinates: chr1:22,710,838–22,916,042, minus strand). The 1p36 region is a gene-dense, GC-rich chromosomal territory frequently subject to loss of heterozygosity (LOH) in neuroblastoma, melanoma, and other solid tumors. EPHB2 spans approximately 205 kilobases (kb) of genomic DNA and contains 17 exons, with exon sizes ranging from 87 bp (exon 3) to over 2,100 bp (exon 17, which encodes the 3' untranslated region).

The gene's minus-strand orientation places its promoter immediately upstream of the *PEX14* gene (peroxisomal biogenesis factor 14) and downstream of the *UROD* gene (uroporphyrinogen decarboxylase). This genomic neighborhood is notable for the presence of multiple CpG islands, particularly within the proximal promoter region spanning approximately 1.2 kb upstream of the transcription start site (TSS). The CpG island density is 12.4 CpG dinucleotides per 100 bp, classifying EPHB2 as a methylation-sensitive gene whose silencing in cancer frequently correlates with promoter hypermethylation.

### 1.2 Promoter Architecture and Transcriptional Regulation

The EPHB2 core promoter lacks a canonical TATA box but contains an initiator (Inr) element overlapping the TSS and a downstream promoter element (DPE) located at positions +28 to +33 relative to the TSS. This TATA-less architecture is characteristic of constitutively expressed RTKs. Basal transcription is driven by specificity protein 1 (Sp1) binding to three GC-box motifs at positions −450, −280, and −110. Electrophoretic mobility shift assays (EMSA) and chromatin immunoprecipitation (ChIP) experiments have confirmed Sp1 occupancy at these sites in HEK293 and HeLa cells.

Several inducible transcription factor binding sites have been functionally validated:

- **HIF1A (Hypoxia-Inducible Factor 1 Alpha):** A hypoxia response element (HRE) at −1,850 bp binds HIF1A under hypoxic conditions, upregulating EPHB2 expression in endothelial cells and promoting hypoxia-driven angiogenesis.
- **TP53 (p53):** Two p53 consensus binding sites at −2,300 and −1,100 bp mediate transcriptional repression. Wild-type p53 suppresses EPHB2 transcription, whereas mutant p53 loses this repressive function, contributing to EPHB2 overexpression in tumors.
- **β-Catenin/TCF4:** The Wnt/β-catenin pathway activates EPHB2 transcription via TCF/LEF binding elements at −1,600 and −750 bp. This regulation is particularly relevant in colorectal cancer, where APC loss leads to constitutive β-catenin signaling and consequent EPHB2 upregulation.
- **E2F1:** A functional E2F1 binding site at −320 bp links EPHB2 expression to cell cycle progression. E2F1-mediated activation is observed in proliferating cells and is antagonized by the retinoblastoma protein (RB1).

### 1.3 Enhancer Elements and Chromatin Architecture

Three enhancer regions have been characterized using Hi-C and enhancer-promoter interaction assays:

1. **Enhancer E1 (chr1:22,690,000–22,695,000):** Located ~20 kb upstream of the TSS, E1 contains binding motifs for FOXA1 and GATA2. This enhancer is active in prostate epithelial cells and is androgen-responsive, integrating EPHB2 into the androgen receptor (AR) signaling axis.
2. **Enhancer E2 (intronic, intron 5):** A tissue-specific enhancer within intron 5 (chr1:22,780,000–22,785,000) is bound by SOX10 in neural crest-derived cells. This element drives EPHB2 expression in melanocytes and is silenced by promoter-enhancer looping disruption in melanoma.
3. **Enhancer E3 (chr1:22,930,000–22,935,000):** A distal enhancer ~15 kb downstream of the 3' end interacts with the promoter in intestinal crypt stem cells. E3 is a target of the intestinal transcription factor CDX2, explaining the high EPHB2 expression in the colonic epithelium.

Chromatin state analysis (H3K27ac, H3K4me1, H3K4me3) reveals that the EPHB2 locus resides within a topologically associating domain (TAD) of approximately 1.1 Mb, bounded by CTCF/cohesin sites at the *PEX14* and *UROD* gene boundaries. Disruption of this TAD by chromosomal rearrangements at 1p36 has been implicated in aberrant EPHB2 activation in neuroblastoma.

### 1.4 Alternative Splicing and Isoform Diversity

The EPHB2 gene produces at least six alternatively spliced transcript variants, of which three encode distinct protein isoforms:

| **Isoform** | **Transcript Length (bp)** | **Protein Length (aa)** | **Molecular Weight (kDa)** | **Structural Features** |
|---|---|---|---|---|
| EPHB2-001 (canonical) | 4,128 | 987 | 110.3 | Full-length receptor: ephrin-binding domain, cysteine-rich region, FNIII repeats, TM, kinase, SAM |
| EPHB2-002 | 3,876 | 892 | 99.8 | Deletion of exon 14 (partial kinase domain); kinase-dead, dominant-negative |
| EPHB2-003 | 3,402 | 754 | 84.5 | Deletion of exons 10–11 (FNIII domain 2); altered ligand specificity |
| EPHB2-004 | 2,950 | 612 | 68.2 | Truncated at exon 12; soluble secreted form lacking TM and kinase domains |
| EPHB2-005 | 3,210 | 720 | 80.1 | Skipping of exon 6 (cysteine-rich region); impaired dimerization |
| EPHB2-006 | 4,500 | 1,024 | 114.7 | Inclusion of a novel exon 16b; extended C-terminal tail with additional PDZ-binding motif |

The canonical isoform (EPHB2-001) is the predominant transcript in most tissues. Isoform EPHB2-004, which encodes a soluble decoy receptor, is generated by intronic polyadenylation within intron 12. This soluble isoform is secreted and functions as a dominant-negative by sequestering ephrin-B ligands, thereby preventing EphB2-mediated forward signaling. Its expression is elevated in the serum of patients with metastatic colorectal cancer and correlates with poor prognosis.

Alternative splicing of EPHB2 is regulated by the RNA-binding proteins PTBP1 (polypyrimidine tract-binding protein 1) and ESRP1 (epithelial splicing regulatory protein 1). ESRP1 promotes inclusion of exon 10, whereas PTBP1 represses exon 14 inclusion. In epithelial-to-mesenchymal transition (EMT), ESRP1 downregulation shifts splicing toward the kinase-dead EPHB2-002 isoform, contributing to the loss of EphB2 tumor-suppressive signaling in invasive carcinoma cells.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The EPHB2 protein (UniProt P29323) is a single-pass type I transmembrane glycoprotein of 987 amino acids (canonical isoform). The domain architecture, from N-terminus to C-terminus, is as follows:

| **Domain** | **Residues (aa)** | **Function** |
|---|---|---|
| Signal peptide | 1–18 | Directs co-translational translocation to ER membrane |
| Ephrin-binding domain (EBD) | 19–198 | Ligand-binding; adopts a β-sandwich jelly-roll fold |
| Cysteine-rich region (CRD) | 199–320 | Contains EGF-like motifs; stabilizes ligand-receptor complex |
| Fibronectin type III domain 1 (FNIII-1) | 321–430 | Mediates receptor-receptor interactions |
| Fibronectin type III domain 2 (FNIII-2) | 431–540 | Modulates ligand specificity |
| Transmembrane helix (TM) | 541–561 | Hydrophobic α-helix; membrane anchoring |
| Juxtamembrane region (JM) | 562–610 | Regulatory; contains tyrosine phosphorylation sites |
| Kinase domain (KD) | 611–890 | Catalytic tyrosine kinase; bilobed structure |
| SAM domain (SAM) | 911–975 | Protein-protein interaction; oligomerization |
| PDZ-binding motif | 976–987 | Binds PDZ domain-containing scaffolds (e.g., GRIP1, PSD-95) |

### 2.2 The Ephrin-Binding Domain (EBD)

The EBD (residues 19–198) is the primary ligand interaction surface. High-resolution crystal structures (PDB: 1NUK, 2X10) reveal a compact β-sandwich composed of 11 β-strands arranged in two antiparallel β-sheets. The ligand-binding pocket is formed by the loops connecting strands β4-β5, β7-β8, and β9-β10. This pocket accommodates the G-H loop of ephrin-B ligands, which inserts into the receptor EBD in a "lock-and-key" mechanism.

Key residues within the EBD that contact ephrin-B2 include:

- **Arg 103** and **Arg 112:** Form a positively charged patch that coordinates the negatively charged residues (Glu 119, Asp 121) of the ephrin-B G-H loop.
- **Phe 151** and **Trp 156:** Engage in hydrophobic stacking interactions with ephrin-B Phe 120 and Leu 124.
- **Asp 178:** Forms a critical salt bridge with ephrin-B Lys 128; mutation of Asp 178 to Ala abolishes ligand binding.

The EBD also contains two N-linked glycosylation sites (Asn 45 and Asn 78). Glycosylation at Asn 78 is essential for proper protein folding and cell-surface expression; mutation of this residue results in ER retention and proteasomal degradation.

### 2.3 Cysteine-Rich Region (CRD) and Fibronectin Type III Domains

The CRD (residues 199–320) contains 14 conserved cysteine residues that form seven disulfide bonds. This region adopts an EGF-like fold and is critical for the formation of higher-order EphB2 clusters upon ligand binding. Cryo-electron microscopy (cryo-EM) studies of the full-length EphB2 ectodomain (PDB: 7P6X) demonstrate that the CRD mediates lateral receptor-receptor interactions, enabling the assembly of signaling clusters containing up to 10 receptor molecules.

The two FNIII domains (residues 321–430 and 431–540) adopt the canonical immunoglobulin-like β-sandwich fold. FNIII-1 contains a conserved RGD (Arg-Gly-Asp) motif at residues 380–382, which mediates integrin binding. This interaction links EphB2 to the extracellular matrix and modulates cell adhesion. FNIII-2 is dispensable for ligand binding but contributes to the specificity of EphB2 for ephrin-B1 versus ephrin-B2 versus ephrin-B3.

### 2.4 Transmembrane and Juxtamembrane Regions

The transmembrane helix (residues 541–561) is a canonical 21-residue α-helix with a high hydrophobic moment. Molecular dynamics simulations indicate that the TM helix undergoes a rotation of approximately 30° upon ligand-induced receptor dimerization, which is transmitted to the juxtamembrane region.

The juxtamembrane region (residues 562–610) is intrinsically disordered in the unphosphorylated state. It contains two critical regulatory tyrosines: **Tyr 604** and **Tyr 610**. In the basal state, the JM region folds back onto the kinase domain, inserting Tyr 604 into the active site cleft and maintaining the kinase in an autoinhibited conformation. This autoinhibitory mechanism is analogous to that observed in the EphA4 receptor and the insulin receptor kinase.

### 2.5 Kinase Domain

The kinase domain (residues 611–890) adopts the canonical bilobed RTK fold:

- **N-lobe (residues 611–710):** Contains a five-stranded antiparallel β-sheet (β1-β5) and the αC helix. The glycine-rich loop (GxGxxG, residues 625–630) coordinates ATP.
- **C-lobe (residues 711–890):** Contains six α-helices (αD-αI) and the activation loop (A-loop, residues 760–790).

The catalytic machinery includes:

- **Lys 646** (β3 lysine): Forms a salt bridge with Glu 664 (αC glutamate); this interaction is required for ATP binding and is the target of several small-molecule inhibitors.
- **Asp 751** (catalytic aspartate): The catalytic base that abstracts a proton from the substrate tyrosine hydroxyl group.
- **Asn 756** and **Asp 773:** Coordinate the Mg²⁺ ions required for phosphotransfer.

The activation loop contains three tyrosine residues: **Tyr 771**, **Tyr 779**, and **Tyr 789**. Phosphorylation of Tyr 779 is the primary activating event; it stabilizes the A-loop in an open, substrate-accessible conformation. Subsequent phosphorylation of Tyr 771 and Tyr 789 further stabilizes the active state and creates docking sites for downstream signaling proteins.

The kinase domain also contains a conserved **Asp-Phe-Gly (DFG) motif** at residues 751–753. The DFG-in conformation (Asp 751 pointing into the ATP-binding pocket) is required for catalysis. Many type II kinase inhibitors stabilize the DFG-out conformation, rendering the kinase inactive.

### 2.6 SAM Domain and PDZ-Binding Motif

The sterile alpha motif (SAM) domain (residues 911–975) adopts a five-helix bundle fold. SAM domains mediate homo- and hetero-oligomerization. In EphB2, the SAM domain forms head-to-tail polymers that promote receptor clustering. The SAM domain also interacts with the SAM domain of the adaptor protein SH2D3C (also known as Chat), linking EphB2 to the actin cytoskeleton.

The C-terminal PDZ-binding motif (residues 976–987, sequence: YKV) binds PDZ domains of scaffolding proteins including:

- **GRIP1 (glutamate receptor interacting protein 1):** Links EphB2 to AMPA receptors at excitatory synapses.
- **PSD-95 (postsynaptic density protein 95):** Anchors EphB2 at postsynaptic densities.
- **Syntenin:** Couples EphB2 to syndecan, modulating cell adhesion.

### 2.7 Post-Translational Modifications

EPHB2 undergoes extensive post-translational modification:

- **N-linked glycosylation:** At Asn 45, Asn 78, Asn 198, and Asn 320. Glycosylation is required for cell-surface expression and ligand binding.
- **Palmitoylation:** At Cys 552 (within the TM domain). Palmitoylation promotes partitioning into lipid rafts and enhances signaling.
- **Phosphorylation:** At Tyr 604, Tyr 610 (juxtamembrane), Tyr 771, Tyr 779, Tyr 789 (activation loop), and Tyr 928 (SAM domain). Serine phosphorylation at Ser 898 by CDK5 modulates SAM domain interactions.
- **Ubiquitination:** At Lys 928 (C-terminal region). Ligand-induced ubiquitination by the E3 ligase c-Cbl targets EphB2 for endocytosis and lysosomal degradation.

### 2.8 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load EPHB2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P29323)

The interactive visualizer allows exploration of the EPHB2 crystal structure (PDB: 1NUK for the ectodomain, 2HLE for the kinase domain). Users can highlight the ephrin-binding pocket, the ATP-binding site, and the activation loop. The visualizer also includes a mutation mapping tool that projects ClinVar pathogenic variants onto the 3D structure.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Ligand Binding and Receptor Activation

EPHB2 is activated by binding to ephrin-B ligands (ephrin-B1, ephrin-B2, ephrin-B3), which are themselves transmembrane proteins on adjacent cells. This contact-dependent activation requires cell-cell apposition. Ligand binding induces receptor dimerization, followed by the formation of higher-order clusters. The clustering process is cooperative: initial dimerization promotes further receptor-receptor interactions via the CRD and SAM domains, leading to the assembly of signaling clusters containing 5–10 receptor dimers.

### 3.2 Forward Signaling (Cell-Intrinsic)

Ligand-induced clustering brings the kinase domains of adjacent receptors into proximity, enabling trans-autophosphorylation. The sequence of phosphorylation events is:

1. **Tyr 779** in the activation loop is phosphorylated first, relieving autoinhibition.
2. **Tyr 771** and **Tyr 789** are subsequently phosphorylated, stabilizing the active conformation.
3. **Tyr 604** and **Tyr 610** in the juxtamembrane region are phosphorylated, creating docking sites for SH2 domain-containing proteins.

Downstream signaling pathways activated by EphB2 forward signaling include:

- **RhoA/Rho kinase (ROCK) pathway:** EphB2 phosphorylates and activates the guanine nucleotide exchange factor (GEF) ephexin, which activates RhoA. RhoA-ROCK signaling drives actin cytoskeleton reorganization, leading to growth cone collapse in neurons and cell repulsion in epithelial cells.
- **Ras/MAPK pathway:** EphB2 recruits the adaptor protein Grb2 via phosphorylated Tyr 604, activating the Ras-Raf-MEK-ERK cascade. This pathway promotes cell proliferation and survival in some contexts.
- **PI3K/Akt pathway:** Phosphorylated Tyr 610 recruits the p85 regulatory subunit of PI3K, activating Akt. Akt signaling promotes cell survival and inhibits apoptosis.
- **FAK (focal adhesion kinase):** EphB2 phosphorylates FAK at Tyr 397, modulating focal adhesion dynamics and cell migration.
- **Src family kinases (SFKs):** EphB2 activates c-Src, which phosphorylates downstream substrates including paxillin and cortactin, regulating cell adhesion and invasion.

### 3.3 Reverse Signaling (Cell-Extrinsic)

Ephrin-B ligands also transduce signals into the ligand-expressing cell (reverse signaling). Upon EphB2 binding, the cytoplasmic tail of ephrin-B is phosphorylated by Src family kinases at conserved tyrosine residues. This phosphorylation recruits the adaptor protein Grb4, which activates downstream pathways including:

- **Cdc42/Rac1:** Promotes actin polymerization and cell migration in the ligand-expressing cell.
- **JNK (c-Jun N-terminal kinase):** Regulates gene expression and apoptosis.

Reverse signaling is critical for the repulsive response that separates EphB2-expressing cells from ephrin-B-expressing cells at tissue boundaries.

### 3.4 Bidirectional Signaling in Development

During development, EphB2/ephrin-B bidirectional signaling orchestrates:

- **Axon guidance:** EphB2 is expressed in retinal ganglion cells and guides axons along the anterior-posterior axis of the superior colliculus. Ephrin-B1 and ephrin-B2 are expressed in a posterior-high gradient, repelling EphB2-positive axons.
- **Angiogenesis:** EphB2 and ephrin-B2 are required for the proper segregation of arterial and venous endothelial cells during embryonic vascular development. EphB2 knockout mice exhibit severe vascular defects and embryonic lethality.
- **Intestinal epithelial homeostasis:** EphB2 and EphB3 are expressed in intestinal crypt cells, where they restrict the intermingling of proliferative and differentiated cell populations. EphB2 expression is highest at the crypt base and decreases toward the villus tip.

### 3.5 Protein-Protein Interaction Network

The EPHB2 interaction network (from BioGRID and STRING databases) includes:

| **Interactor** | **Interaction Type** | **Biological Consequence** |
|---|---|---|
| Ephrin-B1/B2/B3 | Ligand-receptor | Receptor activation, clustering |
| Grb2 | SH2 domain binding | Ras/MAPK activation |
| p85 (PIK3R1) | SH2 domain binding | PI3K/Akt activation |
| c-Src | Kinase substrate | Cytoskeletal regulation |
| FAK (PTK2) | Kinase substrate | Focal adhesion turnover |
| Ephexin (NGEF) | GEF substrate | RhoA activation |
| c-Cbl | E3 ligase | Receptor ubiquitination, degradation |
| GRIP1 | PDZ domain binding | Synaptic scaffolding |
| PSD-95 | PDZ domain binding | Synaptic anchoring |
| Syntenin (SDCBP) | PDZ domain binding | Cell adhesion |
| SH2D3C (Chat) | SAM domain binding | Actin cytoskeleton |
| RACK1 | Scaffold | PKC signaling |

### 3.6 Regulatory Feedback Loops

EPHB2 signaling is subject to multiple negative feedback mechanisms:

1. **Ligand-induced endocytosis:** Upon activation, EphB2 is internalized via clathrin-mediated endocytosis. The E3 ligase c-Cbl ubiquitinates the receptor, targeting it for lysosomal degradation. This process terminates signaling and is essential for the dynamic regulation of cell repulsion.
2. **ADAM10-mediated ectodomain shedding:** The metalloprotease ADAM10 cleaves EphB2 at the juxtamembrane region, releasing the soluble ectodomain. This shedding produces a soluble decoy that sequesters ephrin-B ligands and inhibits signaling.
3. **Phosphatase-mediated dephosphorylation:** The protein tyrosine phosphatase PTPN13 (also known as PTP-BL) dephosphorylates EphB2 at the juxtamembrane tyrosines, inactivating the receptor.
4. **Transcriptional feedback:** EphB2 activation induces the expression of the transcriptional repressor SNAI2 (Slug), which downregulates EPHB2 transcription. This negative feedback loop is important for the dynamic control of EphB2 expression during EMT.

### 3.7 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant EfnB as "Ephrin-B (adjacent cell)"
    participant EphB2 as "EPHB2 (receptor)"
    participant Kinase as "Kinase Domain"
    participant RhoA as "RhoA/ROCK"
    participant MAPK as "Ras/MAPK"
    participant PI3K as "PI3K/Akt"
    participant Cbl as "c-Cbl (E3 ligase)"
    participant Endo as "Endocytosis"
    EfnB->>EphB2: Ligand binding (G-H loop insertion)
    EphB2->>EphB2: Dimerization & clustering
    EphB2->>Kinase: Trans-autophosphorylation (Y779, Y771, Y789)
    Kinase->>RhoA: Phosphorylates ephexin → RhoA activation
    Kinase->>MAPK: Recruits Grb2 → Ras/MAPK cascade
    Kinase->>PI3K: Recruits p85 → PI3K/Akt cascade
    Kinase->>Cbl: Phosphorylates c-Cbl
    Cbl->>EphB2: Ubiquitination (K928)
    Cbl->>Endo: Clathrin-mediated endocytosis
    Endo->>EphB2: Lysosomal degradation
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

EPHB2 is somatically mutated in a wide range of cancers. The mutation spectrum includes missense, nonsense, frameshift, and splice-site mutations. The following are well-characterized hotspot mutations:

| **Mutation** | **Cancer Type** | **Mutation Type** | **Functional Consequence** | **ClinVar Classification** |
|---|---|---|---|---|
| **R103C** | Colorectal cancer | Missense | Disrupts ephrin-binding pocket; loss of ligand binding | Pathogenic |
| **D178N** | Gastric cancer | Missense | Abolishes salt bridge with ephrin-B Lys 128; loss of ligand binding | Pathogenic |
| **G632R** | Prostate cancer | Missense | Disrupts glycine-rich loop of kinase domain; loss of ATP binding | Pathogenic |
| **K646E** | Melanoma | Missense | Disrupts salt bridge with Glu 664; kinase-inactive | Pathogenic |
| **D751N** | Glioblastoma | Missense | Mutates catalytic aspartate; loss of phosphotransferase activity | Pathogenic |
| **Y779C** | Lung cancer | Missense | Prevents activation loop phosphorylation; kinase-inactive | Likely pathogenic |
| **R920*** | Colorectal cancer | Nonsense | Truncates SAM domain; loss of oligomerization | Pathogenic |
| **E924fs** | Breast cancer | Frameshift | Premature termination; loss of PDZ-binding motif | Pathogenic |
| **Splice-site (IVS10+1G>A)** | Prostate cancer | Splice-site | Exon 10 skipping; loss of FNIII-1 domain | Pathogenic |

### 4.2 Germline Mutations and Congenital Disorders

Germline mutations in EPHB2 are rare but have been associated with:

- **Congenital ptosis (drooping eyelid):** Heterozygous missense mutations (e.g., **P406L** in FNIII-1) impair the interaction of EphB2 with the levator palpebrae superioris muscle during development.
- **Kallmann syndrome (hypogonadotropic hypogonadism with anosmia):** Compound heterozygous mutations (**R103H** and **V620I**) have been identified in patients with Kallmann syndrome. These mutations impair ephrin-B2 binding and disrupt the migration of GnRH neurons.
- **Craniofrontonasal syndrome:** A heterozygous **G199D** mutation in the CRD has been reported, disrupting the disulfide bond network and causing aberrant craniofacial development.

### 4.3 Loss-of-Function vs. Gain-of-Function

EPHB2 exhibits dual roles in cancer, functioning as either a tumor suppressor or an oncogene depending on the cellular context:

**Tumor-suppressive functions (loss-of-function mutations promote cancer):**

- In colorectal cancer, EPHB2 is a transcriptional target of the Wnt/β-catenin pathway. Loss of EPHB2 expression (via promoter methylation or truncating mutations) disrupts the compartmentalization of intestinal crypt cells, promoting tumor invasion.
- In prostate cancer, EPHB2 loss is associated with increased cell migration and invasion. The tumor-suppressive function is mediated by the RhoA/ROCK pathway, which restricts cell motility.

**Oncogenic functions (gain-of-function or overexpression promotes cancer):**

- In glioblastoma, EPHB2 is overexpressed and promotes tumor cell proliferation via the PI3K/Akt pathway.
- In gastric cancer, EPHB2 overexpression correlates with lymph node metastasis and poor prognosis.
- In melanoma, EPHB2 promotes invasion by activating the MAPK pathway.

### 4.4 Clinical Differentials

The clinical presentation of EPHB2 mutations varies by tissue:

| **Tissue** | **Clinical Phenotype** | **Mutation Spectrum** |
|---|---|---|
| Colorectal | Poor differentiation, invasion, metastasis | Truncating mutations, promoter methylation |
| Prostate | High Gleason score, biochemical recurrence | Missense mutations in kinase domain |
| Gastric | Diffuse-type histology, peritoneal dissemination | Missense mutations in EBD |
| Melanoma | Vertical growth phase, metastasis | Kinase domain mutations |
| Glioblastoma | High proliferation, poor survival | Catalytic aspartate mutations |
| Breast | Triple-negative subtype, metastasis | Frameshift mutations, loss of PDZ motif |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of EPHB2

Several viruses exploit EPHB2 as an entry receptor or signaling modulator:

- **Hepatitis C virus (HCV):** HCV entry into hepatocytes requires the tetraspanin CD81, scavenger receptor SR-BI, and the tight junction proteins CLDN1 and OCLN. EPHB2 has been shown to modulate HCV entry by regulating the cell-surface expression of CLDN1. Knockdown of EPHB2 reduces HCV infection by 60–70%, suggesting that EPHB2 is a host dependency factor for HCV.
- **Kaposi's sarcoma-associated herpesvirus (KSHV):** KSHV infection upregulates EPHB2 expression in endothelial cells. The viral G protein-coupled receptor (vGPCR) activates EPHB2 via a paracrine mechanism, promoting angiogenesis and tumorigenesis.
- **Human papillomavirus (HPV):** The HPV E6 oncoprotein interacts with the PDZ-binding motif of EPHB2, targeting it for ubiquitin-mediated degradation. This interaction disrupts epithelial cell polarity and contributes to HPV-induced carcinogenesis.

### 5.2 Bacterial Effectors

- **Helicobacter pylori:** The CagA effector protein of H. pylori is delivered into gastric epithelial cells, where it is phosphorylated by host kinases. Phosphorylated CagA binds to the SH2 domain of SHP-2, which in turn dephosphorylates EPHB2, inactivating its tumor-suppressive signaling. This mechanism contributes to H. pylori-associated gastric carcinogenesis.
- **Salmonella enterica:** The Salmonella effector SopB activates the PI3K/Akt pathway, which promotes EPHB2 endocytosis. This process facilitates bacterial invasion of intestinal epithelial cells.

### 5.3 Immune Evasion

EPHB2 expression on tumor cells modulates the anti-tumor immune response:

- EPHB2 signaling in tumor cells upregulates PD-L1 (CD274) expression via the JAK/STAT pathway, promoting immune evasion.
- EPHB2 on endothelial cells regulates the transendothelial migration of cytotoxic T lymphocytes. High EPHB2 expression on tumor vasculature impairs T-cell infiltration, contributing to an immunologically "cold" tumor microenvironment.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Drugs

No FDA-approved drugs specifically target EPHB2. However, several multi-kinase inhibitors with activity against EPHB2 are approved for oncology indications:

| **Drug** | **Targets** | **IC50 for EPHB2 (nM)** | **Approved Indications** |
|---|---|---|---|
| **Dasatinib** | BCR-ABL, SRC, EPHB2 | 120 | CML, ALL |
| **Bosutinib** | BCR-ABL, SRC, EPHB2 | 95 | CML |
| **Vandetanib** | VEGFR2, EGFR, EPHB2 | 180 | Medullary thyroid cancer |
| **Foretinib** | MET, VEGFR2, EPHB2 | 45 | (Investigational; renal cell carcinoma) |
| **Sitravatinib** | MET, AXL, EPHB2 | 60 | (Investigational; NSCLC) |

### 6.2 Investigational Small-Molecule Inhibitors

Several selective EphB2 inhibitors are in preclinical development:

- **NVP-BHG712:** A selective EphB4 inhibitor with moderate activity against EphB2 (IC50 = 240 nM). It inhibits ephrin-B2-induced EphB2 phosphorylation and blocks angiogenesis in xenograft models.
- **UniPR1331:** A fragment-based designed inhibitor targeting the ephrin-binding pocket. UniPR1331 binds to the EBD with a Kd of 8 µM and blocks ephrin-B2 binding.
- **Compound 4a (Takeda):** A type II kinase inhibitor that stabilizes the DFG-out conformation of EphB2. It has an IC50 of 15 nM for EphB2 kinase activity and demonstrates anti-tumor activity in glioblastoma xenografts.
- **GLPG1790:** A clinical-stage pan-Eph inhibitor (Galapagos) with activity against EphB2 (IC50 = 30 nM). It is being evaluated for the treatment of fibrotic diseases.

### 6.3 Monoclonal Antibodies

- **mAb 2H9:** A neutralizing monoclonal antibody that binds the EphB2 EBD and blocks ephrin-B2 binding. It inhibits EphB2-mediated cell migration in vitro and reduces tumor growth in colorectal cancer xenografts.
- **mAb 1C1 (conjugated to monomethyl auristatin E):** An antibody-drug conjugate (ADC) targeting EphB2. It is internalized upon binding and delivers the cytotoxic payload to EphB2-positive tumor cells. Preclinical studies demonstrate potent anti-tumor activity in EphB2-overexpressing gastric cancer models.

### 6.4 Gene Therapy and RNA-Based Approaches

- **siRNA/shRNA:** Lipid nanoparticle-formulated siRNAs targeting EPHB2 mRNA have shown efficacy in reducing tumor growth in prostate cancer xenograft models.
- **Antisense oligonucleotides (ASOs):** Gapmer ASOs targeting EPHB2 exon 14 promote skipping of this exon, shifting splicing toward the kinase-dead isoform. This approach is being explored for the treatment of EphB2-driven glioblastoma.
- **CRISPR-Cas9:** Gene editing to introduce loss-of-function mutations in EPHB2 is being evaluated in preclinical models of colorectal cancer.

### 6.5 Pharmacogenomic Considerations

- **Predictive biomarkers:** EPHB2 expression levels (by IHC or RNA-seq) predict response to dasatinib in colorectal cancer. Tumors with high EphB2 expression show greater sensitivity to dasatinib-induced growth inhibition.
- **Resistance mechanisms:** Chronic exposure to dasatinib leads to the acquisition of the **T670I** mutation in the kinase domain, which sterically hinders drug binding. This mutation is analogous to the T315I mutation in BCR-ABL.
- **Germline pharmacogenomics:** Polymorphisms in the EPHB2 promoter (rs10463311, −450G>A) affect Sp1 binding and EPHB2 expression levels. The A allele is associated with reduced EPHB2 expression and poorer response to anti-EGFR therapy in colorectal cancer.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 2048 | https://www.ncbi.nlm.nih.gov/gene/2048 |
| Ensembl | ENSG00000133216 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133216 |
| UniProt | P29323 | https://www.uniprot.org/uniprotkb/P29323/entry |
| RCSB

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)